Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Partners With Acceleron On Novel Bone Forming Compound

This article was originally published in The Pink Sheet Daily

Executive Summary

$997 million deal will includes ACE-011 for cancer-related bone loss and other discovery compounds.

You may also be interested in...



Financings Of The Fortnight Hopes 2011 Didn’t Set A (Low) Fundraising Benchmark For 2012

Plus news on recent financings by Warp Drive Bio, Synageva BioPharma, Elevation Pharmaceuticals and Acceleron Pharma.

Acceleron And Celgene Expand Anemia Collaboration With Second Compound

The two companies will split development costs for ACE-536 in anemia-related conditions, and Acceleron will hold North American co-promotion rights.

Acceleron And Celgene Expand Anemia Collaboration With Second Compound

The two companies will split development costs for ACE-536 in anemia-related conditions, and Acceleron will hold North American co-promotion rights.

Related Content

Topics

UsernamePublicRestriction

Register

PS067270

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel